These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11163545)

  • 1. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.
    Lavalaye J; Linszen DH; Booij J; Dingemans PM; Reneman L; Habraken JB; Gersons BP; van Royen EA
    Schizophr Res; 2001 Jan; 47(1):59-67. PubMed ID: 11163545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone].
    Mateos JJ; Lomeña F; Parellada E; Font M; Fernández E; Pavia J; Prats A; Bernardo M
    Rev Esp Med Nucl; 2006; 25(3):159-65. PubMed ID: 16762269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers.
    Lavalaye J; Booij J; Reneman L; Habraken JB; van Royen EA
    Eur J Nucl Med; 2000 Jul; 27(7):867-9. PubMed ID: 10952500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.
    Booij J; Andringa G; Rijks LJ; Vermeulen RJ; De Bruin K; Boer GJ; Janssen AG; Van Royen EA
    Synapse; 1997 Nov; 27(3):183-90. PubMed ID: 9329154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
    Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT.
    Nikolaus S; Wirrwar A; Antke C; Arkian S; Schramm N; Müller HW; Larisch R
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):308-13. PubMed ID: 15791440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers.
    Staley JK; Krishnan-Sarin S; Zoghbi S; Tamagnan G; Fujita M; Seibyl JP; Maciejewski PK; O'Malley S; Innis RB
    Synapse; 2001 Sep; 41(4):275-84. PubMed ID: 11494398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
    Benamer HT; Patterson J; Wyper DJ; Hadley DM; Macphee GJ; Grosset DG
    Mov Disord; 2000 Jul; 15(4):692-8. PubMed ID: 10928580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
    Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA
    Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
    Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
    Tissingh G; Bergmans P; Booij J; Winogrodzka A; van Royen EA; Stoof JC; Wolters EC
    J Neurol; 1998 Jan; 245(1):14-20. PubMed ID: 9457623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
    Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL
    Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.